News
-
-
-
PRESS RELEASE
Inventiva Reports Preliminary 2024 First-Half Financial Information¹
Inventiva reports preliminary 2024 first-half financial information, including cash position, expenses, and funding concerns. No revenues recorded in H1 2024. Company remains focused on clinical trials and upcoming milestones -
-
-
-
-
-
-
PRESS RELEASE
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position
Inventiva updates on its clinical program evaluating lanifibranor for MASH/NASH, with positive recruitment and financial outlook. New patents strengthen the company's position